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Background: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy,
affecting up to 80% of expecting mothers. In April 2013 the FDA approved the delayed release combination of
doxylamine succinate and -pyridoxine hydrochloride (Diclegis®) for NVP, following a phase 3 randomized trial in
pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is
the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its
maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine
succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis® as compared to placebo.
Methods: We randomized women suffering from NVP to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at
doses ranging from 2–4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse
events were collected through patient diaries, clinical examination and laboratory testing.
Results: Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased
rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement.
Conclusions: Doxylamine succinate–pyridoxine hydrochloride delayed release combination is safe and well tolerated
by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of
pregnancy.
Trial Registration: Clinical Trial Registration No: NCT00614445.
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Nausea and vomiting of pregnancy (NVP) affect up to
80% of expecting mothers, and while lifestyle changes
may be helpful, many women need medications to con-
trol their symptoms [1,2].
The delayed-release combination of doxylamine suc-
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unless otherwise stated.commonly used for NVP and was the only drug ap-
proved by the FDA until the manufacturer’s voluntary
removal of it from the market in 1983 [3]. In 1983 [4]
and 1999 [5], the FDA determined that this drug com-
bination was not withdrawn from sale for reasons of
safety and effectiveness. In fact, its removal from the
American market was temporally associated with a 2-
fold increase in rates of hospitalization of pregnant
women for the most severe form of NVP, hyperemesis
gravidarum [6,7]. Over the last 3 decades a large body of
evidence corroborated the fetal safety of this drug com-
bination [8,9].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Comparison of demographic and medical
characteristics of the two study groups in the ITT
population
Diclegis
(n-131)
Placebo
(n = 125)
P-value
Ethnicity: 0.48
Hispanic or Latino 53 (40.5%) 56 (44.8%)
Not Hispanic or Latino 78 (59.5%) 69 (55.2%)
Race: 0.59
Asian 2 (1.5%) 1 (0.8%)
Black or African American 49 (37.4%) 48 (38.4%)
White or Caucasian 80 (61.1%) 73 (58.4%)
Unknown 3 (2.4%)
Previous Pregnancy 101 (77.1%) 94 (75.2%) 0.64
Smoking during pregnancy 17 (13.0%) 16 (12.8%) 0.97
Maternal Age (yr) 25.9 ± 6 25.0 ± 5.7 0.23
Weight (kg) 74.10 ± 22.30 75.91 ± 22.19 0.50
(lbs) 163.35 ± 49.17 167.34 ± 48.91 0.50
BMI (kg/m2): 0.42
Underweight 5 (3.8%) 4 (3.2%)
Normal 39 (29.8%) 38 (30.4%)
Overweight 31 (23.7%) 40 (32.0%)
Obese 55 (42.0%) 42 (33.6%)
BMI (kg/m2) 0.95
Mean ± SD 28.77 ± 7.60 29.67 ± 11.20
Median 27.97 26.83
Gestational age at start of
NVP (weeks)
0.90
Mean ± SD 5.5 ± 1.8 5.4 ± 1.7
Gestational age at enrollment
(weeks)
0.75
Mean ± SD 9.3 ± 2.0 9.3 ± 1.8
PUQE score at Enrollment 0.44
Mean ± SD 9.0 ± 2.1 8.8 ± 2.1
Median 9.0 8.0
Global Assessment of
Well Being
Mean ± SD 5.0 ± 2.3 5.4 ± 2.2
Median 5.0 5.0
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this combination is to allow women to take it before
bedtime, when symptoms of NVP tend to be minimal, in
order to counteract the increased symptoms more com-
monly experienced in the morning hours [10,11]. In
April 2013, the FDA approved the sale of Diclegis®, an
identical combination to the original Bendectin® and its
Canadian equivalent Diclectin®, after a randomized
blinded placebo- controlled trial [12]. The fetal safety of
this medication has been proven by numerous studies.
However, since it is the only FDA-approved medication
for NVP, it is likely to be used by a large number of
pregnant women, confirming maternal safety is an im-
portant public health question.
The objective of this study was to evaluate the mater-
nal safety of Diclegis® in treating NVP compared to
placebo.
Methods
This is a secondary analysis of a double-blind, random-
ized, multicenter, placebo-controlled study of the delayed-
release combination of doxylamine succinate (10 mg) and
pyridoxine hydrochloride (10 mg) (Diclegis®) in the treat-
ment of NVP [12]. The study was approved by the IRB of
the University of Texas, Galveston, University of Pittsburg
and Georgetown University. The subjects were pregnant,
at least 18 years of age, in the gestational age range of 7–
14 weeks, suffering from NVP, had a PUQE score ≥ 6)
[13-15], and had not responded to conservative manage-
ment consisting of dietary/lifestyle advice [16]. Women
treated by other antiemetics, suffering from chronic med-
ical conditions, or those who could not communicate in
either English or Spanish, were excluded. After physical
examination and laboratory tests (hemoglobin and blood
count, liver function tests, electrolytes, amylase), and after
confirming in utero singleton pregnancies by ultrasound,
women were randomized, using a computerized program,
to receive Diclegis® (doxylamine succinate 10 mg and pyri-
doxine hydrochloride 10 mg) or placebo of similar look.
Two tablets of study drug (Diclegis® or placebo) were ad-
ministered at bedtime on Day 1. If symptoms of nausea
and vomiting persisted into the afternoon hours of Day 2
(i.e., PUQE Score above 3), the subject was directed to
take her usual dose of 2 tablets at bedtime and an add-
itional tablet the next morning on Day 3. Based upon as-
sessment in the clinic on Day 4 (+/−1 day), the subject
might have been directed to take an additional 4th tablet
mid-afternoon to control evening symptoms. The mini-
mum assigned study medication was 2 tablets daily at bed-
time, increasing when indicated to the maximal dosage of
4 tablets per day according to the timing, duration, sever-
ity, and frequency of the symptoms experienced by the
subject. The study had a 15 day period consisting of 14
dosing days. Telephone contact was made on day 2, 6, 12,and 14 in order to assess subject diary information, ad-
verse events (AEs), concomitant medications, and com-
pliance with the study medication. Patients returned to
the clinic in the morning prior to their morning dose on
Day 4 (+/− 1 day), Day 8 (+/− 1 day), and on Day 15 (+/−
1 day; end of study visit) to collect diary report and
complete all study related data.
Subjects completed the Pregnancy-Unique Quantifica-
tion of Emesis (PUQE) score and the study diary (once
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the same time each day). They also completed the Glo-
bal Assessment of Well Being scale of the PUQE on
Days 1, 8, and 14 at the same time the PUQE score was
completed.
Adverse events and concomitant medications were re-
corded at all visits and follow-up phone calls. An add-
itional follow-up phone call was conducted 30 days after
last dosing to capture serious adverse events for patients
completing the treatment period or early termination.
The results of the effectiveness of the drug in this trial
have been previously published [12].
The frequency and severity of all AEs were tabulated by
treatment group, system organ class, preferred term sever-
ity, and relationship to study drug. In addition, laboratory
tests were conducted on Days 1 and15 (±1 day).
Adverse events (AEs) experienced by the subjects that
occurred on or after Day 1 (after the patient signed the
informed consent form) through Day 15, were compared
between groups using Pearson’s Chi-square test or Fisher’s
exact test if more appropriate. The available sample size
has 80% power to show a doubling in CNS depression
with alpha of 5%.
Results
Two hundred and eighty-three pregnant women experi-
encing NVP were enrolled and randomized. After writ-
ten informed consent nine subjects randomized to
Diclegis® (6.4%) and 18 randomized to Placebo (12.9%)Table 2 Overall summary of tolerability/adverse events for IT
Measure of tolerability
Number of Subjects with at least one treatment-emergent AE
Number of Subjects with a serious treatment-emergent AE
Number of Subjects with at least one Related AE
Number of Subjects discontinuing study drug due to AE
Number of deaths
Overall treatment0emergent AEs
Number of Subjects with at least one Mild AE
Number of Subjects with at least one Moderate AE
Number of Subjects with at least one Severe AE
Number of Subjects with Unrelated AE
Number of Subjects with at least one Possibly Related AE
Number of Subjects with at least one Probably Related AE
Number of Subjects with at least on Definitely Related AE
1The p-value for comparing Treatment groups uses Chi-square test method.
2P-value is calculated using Fisher’s exact test method.
Related category includes Possible, Probable, and Definite relationships. Unrelated c
Subjects reporting more than one AE will only be counted under the strongest rela
Mild: asymptomatic or mild symptoms, intervention not needed; Moderate: minimawithdrew consent. Therefore, 131 women in Diclegis®
treated group and 125 receiving placebo were analyzed.
The two groups did not differ in any demographic or
medical characteristics (Table 1).
The use of Diclegis® was not associated with an overall
increased rate of adverse effects as compared to the
Placebo group (Table 2). Of particular interest, the active
drug was not associated with increased rates of symp-
toms known to be associated with antihistamines, such
as sedation, symptoms of CNS depression and gastro-
intestinal or anticholinergic symptoms (Table 3). Diclegis®
was also not associated with either more frequently occur-
ring adverse events (Table 4), or with an increase in Treat-
ment Emergent Adverse Events (TEAEs) -as defined by the
investigators, blinded to study drug allocation (Table 5).
TEAEs were defined as any adverse event that emerged
after the treatment (either the drug or the placebo) were
commenced.
Discussion
The randomized trial described herein has previously
shown the superiority of Diclegis® over placebo in treat-
ing the symptoms of NVP in American women managed
in 3 academic centers [12].
In Canada, the doxylamine succinate-pyridoxine hydro-
chloride combination (Diclectin®) has been available since
1979 [17], with a large number of studies corroborating
the initial FDA evaluation of its efficacy and safety
[18-20]. The present study had a placebo arm, asT-S subjects
Treatment group
Diclegis
(N = 131)
Placebo
(N = 127)
P-value1
74 (56.5%) 65 (51.2%) 0.393
4 (3.1%) 4 (3.1%) 1.0002
40 (30.5%) 32 (25.2%) 0.339
6 (4.6%) 4 (3.1%) 0.7492
0 0 _
62 (47.3%) 59 (46.5%) 0.221
5 (3.8%) 1 (0.8%) 0.2152
7 (5.3%) 5 (3.9%) 0.711
34 (26.0%) 33 (26.0%) 0.570
24 (18.3%) 23 (18.1%) 0.714
13 (9.9%) 8 (6.3%) 0.388
3 (2.3% 1 (0.8%) 0.6232
ategory includes unlikely and not related.
tionship and/or severity.
l, local or non invasive intervention indicated; Severe: medically significant.
Table 3 Treatment Emergent Adverse Events (TEAEs) in
the study for ITT-S subjects
Treatment group
System Organ Class (SOC)
preferred term
Diclegis
(N = 131)
Placebo
(N = 127)
P-value1
# of Subjects with at least one TEAE 74 (56.5%) 65 (51.2%) 0.39
Cardiac disorders 1 (0.8%) 1 (0.8%) 1.0002
Palpitations 1 (0.8%) 1 (0.8%) 1.0002
Eye disorders 1 (0.8%) 0 1.0002
Dry eye 1 (0.8%) 0 1.0002
Gastrointestinal disorders 23 (17.6%) 22 (17.3%) 0.960
Constipation 2 (1.5%) 2 (1.6%) 1.0002
Dry mouth 4 (3.1%) 1 (0.8%) 0.3702
Haematemesis 0 1 (0.8%) 0.4922
Feeling jittery 1 (0.8%) 0 1.0002
Laboratory Investigations 7 (5.3%) 6 (4.7%) 0.820
Alanine aminotransferase increased 0 1 (0.8%) 0.4922
Aspartate aminotransferase increased 0
Blood albumin decreased 1 (0.8%) 0 1.0002
Blood amylase increased 2 (1.5%) 2 (1.6%) 1.0002
Blood chloride decreased 0 1 (0.8%) 0.4922
Blood creatinine increased 1 (0.8%) 1 (0.8%) 1.0002
Blood lactate dehydrogenase
increased
1 (0.8%) 0 1.0002
Blood sodium decreased 0 1 (0.8%) 0.4922
Blood triglycerides increased 1 (0.8%) 0
Gamma-glutamyltransferase
increased
1 (0.8%) 1 (0.8%) 1.0002
Heart rate increased 0 1 (0.8%) 0.4922
Platelet count decreased 1 (0.8%) 0 1.0002
Nervous system disorders 42 (32.1%) 37 (29.1%) 0.610
Dizziness 8 (6.1%) 8 (6.3%) 0.949
Headache 17 (13.0%) 20 (15.7%) 0.526
Loss of consciousness 0 1 (0.8%) 0.4922
Poor quality sleep 1 (0.8%) 0 1.0002
Somnolence 19 (14.5%) 15 (11.8%) 0.523
Syncope 1 (0.8%) 1 (0.8%) 1.0002
Fatigue 9 (6.9%) 8 (6.3%) 0.853
1The p-value for comparing Treatment groups uses Chi-square test method.
2P-value is calculated using Fisher’s exact test method.
At each level of summarization (SOC/preferred term), subjects reporting more
than one AE will only be counted once.
Table 4 Most frequently occurring Treatment Emergent
Adverse Events (TEAEs) in the study for ITT-S subjects
Treatment group
System Organ Class (SOC)
preferred term
Diclegis
(N = 131)
Placebo
(N = 127)
P-value1
# of Subjects with at least one TEAE 74 (56.5%) 65 (51.2%) 0.393
Gastrointestinal disorders 23 (17.6%) 22 (17.3%) 0.960
Abdominal pain 5 (3.8%) 8 (6.3%) 0.362
General disorders and
administration site
13 (9.9%) 12 (9.4%) 0.897
Conditions
Fatigue 9 (6.9%) 8 (6.3%) 0.949
Musculoskeletal and
connective tissue
11 (8.4%) 4 (3.1%) 0.072
Disorders
Back pain 7 (5.3%) 4 (3.1%) 0.383
Nervous system disorders 42 (32.1%) 37 (29.1%) 0.610
Dizziness 8 (6.1%) 8 (6.3%) 0.949
Headache 17 (13.0%) 20 (15.7%) 0.526
Somnolence 19 (14.5%) 15 (11.8%) 0.523
1The p-value for comparing Treatment groups uses Chi-square test method.
TEAEs that are considered most frequently occurring include the events (in
preferred terms) reported by at least 5% of subjects in any of the treatment
groups.
At each level of summarization (SOC/preferred term), subjects reporting more
than one AE will only be counted once.
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women by the end of the first trimester [1]. In addition,
when considering maternal safety associated with the first
trimester of pregnancy, symptoms such as fatigue, ten-
dency to sleep and dehydration, may be erroneously at-
tributed to the drug, rather than to both pregnancy and
NVP.The use of Diclegis® was not associated with an in-
creased risk of any adverse effects when compared to
placebo, lending important reassurance to its use by
large numbers of pregnant women.
It may be puzzling, however, how symptoms of CNS
depression, so typical of the sedating antihistamines,
were more prevalent in the active arm of the study. The
answer may lie in the demographics of the study popula-
tion as presented in Table 1.
The mean weight of the women in the study was
75 kg (165 lb), rendering 24% of them overweight and
42% obese. When the original Bendectin® studies were
conducted the mean weight of participating women was
20 kg lower on average. As a result we might hypothesize
that the relatively lower weight-adjusted dose given to our
mostly overweight and obese study participants could
have mitigated adverse drug effects.
A previous study determined the incidence of adverse
maternal effects among 225 women taking Diclectin® at
the recommended (n = 123) or higher than recom-
mended (n = 102) doses [21]. One-third (33.6%) of those
women reported having adverse CNS effects (sleepiness,
tiredness, and/or drowsiness) temporally related to the
medication, a rate very similar to the present study
(28.3%). In that study there was no association between
the dose per kg and rates of reported maternal adverse
effects with doses ranging from 0.1 mg/kg to 2.0 mg/kg
Table 5 Treatment Emergent Adverse Events (TEAEs) with respect to relationship to study drug- related vs. unrelated
for ITT-S subjects
Treatment group
Diclegis (N = 131) Placebo (N = 127)
System Organ Class (SOC) preferred term Related Unrelated Related Unrelated
# of Subjects with at least one 40 (30.5%) 34 (26.0%) 32 (25.2%) 33 (26.0%)
TEAE in the study
Cardiac disorders 1 (0.8%) 0 0 1 (0.8%)
Palpitations 1 (0.8%) 0 0 1 (0.8%)
Eye disorders 0 1 (0.8%) 0 0
Dry eye 0 1 (0.8%) 0 0
Gastrointestinal disorders 8 (6.1%) 15 (11.5%) 8 (6.3%) 14 (11.0%)
Abdominal pain 1 (0.8%) 4 (3.1%) 3 (2.4%) 5 (3.9%)
Abdominal pain upper 0 3 (2.3%) 2 (1.6%) 3 (2.4%)
Constipation 1 (0.8%) 1 (0.8%) 1 (0.8%) 1 (0.8%)
Diarrhea 2 (1.5%) 2 (1.5%) 1 (0.8%) 1 (0.8%)
Dry mouth 4 (3.1%) 0 1 (0.8%) 0
Dyspepsia 1 (0.8%) 4 (3.1%) 1 (0.8%) 1 (0.8%)
Flatulence 0 0 0 1 (0.8%)
Salivary hypersecretion 0 0 0 1 (0.8%)
General disorders and administration 7 (5.3%) 6 (4.6%) 6 (4.7%) 6 (4.7%)
Feeling jittery 1 (0.8%) 0 0 0
Nervous system disorders 33 (25.2%) 9 (6.9%) 24 (18.9%) 13 (10.2%)
Dizziness 6 (4.6%) 2 (1.5%) 5 (3.9%) 3 (2.4%)
Headache 8 (6.1%) 9 (6.9%) 8 (6.3%) 12 (9.4%)
Loss of consciousness 0 0 0 1 (0.8%)
Poor quality sleep 0 1 (0.8%) 0 0
Somnolence 19 (14.5%) 0 15 (11.8%) 0
Syncope 1 (0.8%) 0 0 1 (0.8%)
Fatigue 6 (4.6%) 3 (2.3%) 5 (3.9%) 3 (2.4%)
Related category includes Possible, Probable, and Definite relationships. Unrelated category includes unlikely and not related.
At each level of summarization (SOC/preferred term), subjects reporting more than on AE will only be counted once under the strongest relationship.
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dose of Diclectin®, when calculated per kg of body
weight, did not affect either the incidence or severity of
maternal adverse effects. Similarly, no excess was re-
corded for other typical adverse effects of antihistamine,
such as those involved in low gastrointestinal motility or
anticholinergic effects (e.g. dry mouth, dysrhythmia).
In a recent population- based Canadian study, preg-
nant women in the first trimester of pregnancy, when
NVP and the use of Diclegis® is at its peak, did not have
a higher risk of car crushes, whereas there was a 46% in-
creased risk in the second trimester, when most morning
sickness has subsided and the drug is not used [21]. This
may serve as a population-based corroboration of the
present results, showing that Diclegis® is not associated
with measurable CNS depression.Conclusions
Based on this secondary analysis of results from a double
blind placebo controlled trial, the pyridoxine-doxylamine
combination appears to be safe to the pregnant woman
suffering from NVP.
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